Sarepta Therapeutics shares plunged premarket on Friday after the company disclosed another patient death linked to its gene therapy programs, this time during an early-stage trial for limb-girdle ...

Interactive Brokers reported quarterly earnings of 51 cents per share, which beat the analyst consensus estimate of 45 cents.

Shares of Sarepta Therapeutics declined 16.5% in premarket trading on Friday after a Bloomberg report that a trial patient who received an experimental gene therapy has died from liver failure, making ...